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Objectives: To assess the effect of micronutrients on health outcomes in patients with heart failure.
Materials and Methods: Only randomized controlled trials testing the effectiveness of different micro-
nutrients either singly or combined versus placebo in heart failure patients were included. We conducted
a search in different databases such as Medline from PubMed, Embase and Scopus from Elsevier, and
Google Scholar. The keywords used in the search were “Heart Failure” and its cognates, “Micronutrient,”
“Minerals,” and names of individual micronutrients.
Results: Out of 3288 titles and abstracts reviewed, only 11 trials comprising 529 individuals were found
to be appropriate to be included in the ﬁnal review. It was found that micronutrients, either single or
combined, improved the health outcomes of heart failure patients by improving exercise tolerance,
functional capacity, left ventricular function, ﬂow-dependent dilation, and inﬂammatory milieu, thereby
improving the quality of life of health failure patients. Certain micronutrients also normalized endo-
thelial dysfunction.
Conclusion: Overall, this systematic review found sufﬁcient evidence to support a large-scale trial on
micronutrient supplementation in patients with heart failure.
Copyright © 2016, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Heart failure (HF) is a chronic progressive disease which has a
debilitating impact on an individual patient's life [1]. HF is deﬁned
as a syndromewith characteristic symptoms of shortness of breath,
fatigue, ﬂuid retention manifesting as pulmonary congestion and
ankle edema, and abnormalities of either structure or function of
the heart, even at rest [2]. Approximately 1e2% of the adult pop-
ulation in developed countries has HF, with the prevalence rising to
10% or higher among persons aged 70 years [3]. The prevalence of
HF in India, based on disease-speciﬁc estimates due to coronary
heart disease, hypertension, obesity, diabetes, and rheumatic heart
disease, ranges from 1.3 million to 4.6 million with an annual
incidence from 491,600 to 1.8 million [4]. The consequences of HFy Practice, RVS College of
imbatore 641401, Tamil Nadu,
U. Chander).
lief Tzu Chi Foundation. Publishedcontinue to increase with the age of our population [5], as it affects
~10% of those over 80 years old [6]. For HF patients, the age-
adjusted mortality is from four- to eight-fold greater than that of
the general population [7]. The main troublesome features of the
condition are poor prognosis, persistently high readmission rates,
and reduced quality of life [6].
HF is a clinical syndrome which can result from any disorder
that impairs the ability of the ventricle to ﬁll in or eject blood,
therefore making the heart unable to pump blood at a rate sufﬁ-
cient to meet the metabolic demands of the body [8]. This systemic
illness includes the presence of oxidative stress with reactive ox-
ygen and nitrogen intermediates that overwhelm endogenous
antioxidant defenses in diverse tissues such as the skin, skeletal
muscle, heart, peripheral blood mononuclear cells (lymphocytes
and monocytes) and blood, a proinﬂammatory phenotype with
activated peripheral blood mononuclear cells and elevations in
circulating chemokines and cytokines such as interleukin-6 and
tumor necrosis factor-a, and a catabolic state with loss of soft tis-
sues and bone in part due to a negative caloric and nitrogen balance
that eventuates in awasting syndrome termed cardiac cachexia [9].
According to Hippocrates “Dropsy (heart failure) is usuallyby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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the body following a long illness. The ﬂesh is consumed and be-
comes water. The abdomen ﬁlls with ﬂuid; the feet and legs swell;
the shoulders, clavicles, chest and thighs melt away.”
Patients with HF may be more susceptible to the effects of
micronutrient deﬁciency because of increased oxidative stress
(requiring antioxidant protection), impaired skeletal muscle func-
tion (possibly exacerbated by vitamin D deﬁciency), and impaired
myocardial contraction. Some severemicronutrient deﬁciencies can
cause heart failure and, therefore, it is reasonable to expect that less
severe deﬁciency may exacerbate existing cardiac dysfunction [10].
Speciﬁc micronutrient deﬁciencies can cause HF and patients with
HF, usually elderly patients with other conditions, have a number of
risk factors formicronutrient deﬁciency, as they have a poor general
diet and are prone to excess urinary losses due to diuretic therapy
[6]. Due to inadequate intake, altered metabolism, the proin-
ﬂammatory state, increased oxidative stress, and increased nutrient
loss, undernutrition can occur which results in lean body mass
depletion (including vital organs such as the myocardium itself),
with negative implications on functional capacity and increased
postoperative complications and mortality [11].
The adult human heart pumps approximately 5 L of blood per
minute at rest and up to 24 L/min during vigorous exercise, which is
an extreme metabolic demand. Fatty acids are the predominant
energy source. However, carbohydrates can also be easily utilized by
the heart or both carbohydrates and fatty acids simultaneously.
Adenosine triphosphate (ATP) is formed by converting these energy
sources and is hydrolyzed by the heart to continue its pump function
[12]. For this pumping function, it is estimated that over 6 kg of ATP
is hydrolyzed by the heart daily. The enzymes, membranes, and
structural elements of the heart undergo constant turnover and
rebuilding to maintain this essential level of efﬁciency. The entire
heart is reconstructed every 30 days with brand-new protein com-
ponents using a steady supply of nutritional building blocks in the
form of amino acids, lipids, and carbohydrates. With a system of
interconnected cycles, as shown in Fig. 1, energy transfer in the
beating heart can be visualized. The heart receives nutrients through
circulation and transfers energy from nutrients to ATP, which in turn
is used to support cyclic contractions. By either increasing or
decreasing the rate of energy turnover, the system readily responds
to environmental changes under normal conditions [13].Fig. 1. Energy transfer in a beating heart. ATP¼ adenosine triphosphate. Note. From
“Micronutrient deﬁciencies an unmet need in heart failure” by Victor Soukoulis et al,
2009, Journal of the American College of Cardiology, 54, p. 1660e73. Copyright 2009, Name
of CopyrightHolder: Dr. Heinrich Taegtmeyer, Department of InternalMedicine, Division of
Cardiology, University of Texas Houston Medical School, 6431 Fannin, MSB 1.246, Hous-
ton, Texas 77030. E-mail: Heinrich.Taegtmeyer@uth.tmc.edu. Reprinted with permission.Nutrition is an important element of health in the older popu-
lation and affects the aging process [14]. Nutrients are those sub-
stances that the body uses to produce energy, to provide building
blocks for new molecules, and to function in chemical reactions.
Nutrients can be divided into micronutrients, macronutrients, ox-
ygen, and water. Protein, fat, and carbohydrates are the major
organic nutrients or macronutrients and are broken down by en-
zymes into their individual components during digestion [15].
Micronutrients are any essential dietary components and are
important trace elements required for growth, metabolism, and the
normal functioning of the immune system [16,17]. A decreased
intake of macronutrients and micronutrients contributes to the
progression of HF. Therefore, not only should the risk factors of
coronary heart disease be treated, but malnutrition and nutrient
deﬁciencies should also be corrected [18]. Regardless of whether
altered intake or metabolism is responsible, people with chronic
disease and/or increased age may require more tailored nutrition
than the general population to ensure proper nutrients for cellular
repair and metabolism [19]. As HF progresses, nutrient therapy
should be individualized according to a patient's particular re-
quirements [20]. However, very little information on nutrition
therapy is provided in the treatment guidelines for major heart
failure. In the most recent guidelines by of the American Heart
Association and American College of Cardiology Foundation, salt
restriction was recommended for patients with current or prior
symptoms of HF, reduced left ventricular ejection fraction, and
evidence of ﬂuid retention [21]. The Heart Failure Society of
America provides some comprehensive recommendations on diet
and nutrition in their most recent guidelines [22]. According to
these guidelines, nutrition assessment and energy supplementa-
tion are recommended in patients with advanced HF and muscle
wasting. These guidelines also suggest that all patients with HF
should be considered for daily evidence-based multi-
vitaminemineral supplementation, particularly those receiving
diuretic therapy or restricted diets. Hence, the present article tries
to review the data connecting micronutrients and heart failure. The
primary aim of this review is to understand the availability of ev-
idence for and against the use of micronutrients in patients with HF.
2. Materials and Methods
2.1. Search strategy
An extensive search was conducted to select randomized
controlled trials that evaluated the utility of different micro-
nutrients in patients with congestive heart failure (CHF). The da-
tabases used in the searchwereMedline from PubMed, Embase and
Scopus from Elsevier, and Google Scholar. The keywords used in the
search were “Heart Failure” and its cognates, “Micronutrient,”
“Minerals,” and names of individual micronutrients. The inclusion/
exclusion criteria for the selection of trials are shown in Fig. 2.
2.2. Recovery of trials
Our initial search returned 3288 articles out of which 143
potentially relevant articles were identiﬁed. Potentially eligible
studies were identiﬁed by one author by screening titles and ab-
stracts by applying the search keywords. All trials were then
assessed independently by two authors and potentially relevant
studies were selected according to predeﬁned inclusion criteria
(Table 1). Any disagreement was reviewed and resolved by the third
independent reviewer. Authors of individual trials were contacted
if necessary. After reviewing the abstracts, 62 articles did not meet
the inclusion criteria and were excluded from the study. Out of 81
articles that met inclusion criteria, 70 trials did not have enough
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Fig. 2. Flowchart of the article selection process.
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excluded. Only 11 trials were included in the ﬁnal review and
synthesis of results.2.3. Data abstraction and study appraisal
We extracted the following general data from each study:
country of origin, year of publication, number of randomized pa-
tients per each treatment arm, sex ratio, mean age in years, dura-
tion of symptoms, micronutrients used in the trial, dose of each
micronutrient, duration of follow up, and outcomes of the study.The primary outcome of interest was the impact of micronutrients
on the ejection fraction. Secondary outcomes were the impact of
micronutrients on improvement in left ventricular function, exer-
cise capacity, and functional capacity of the patients.2.4. Methodological quality of included trials
The methodological quality of the trials was assessed based on
methods of randomization, allocation concealment, sample size
calculation, blinding, and loss to follow up. The letters A through E
were used to indicate the quality of the methods used in the trial.
Table 1
Inclusion and exclusion criteria for the selection of studies to review.
Inclusion criteria:
1. Studies that reported micronutrient intake in CHF patients, any age, without
date limits.
2. Publications reporting the use of micronutrients either singly or combined in
CHF patients.
3. Publications having randomized controlled trials as their study design.
4. Publications for which peer review was conducted.
Exclusion criteria:
1. Studies published in languages other than English or studies for which
English translation is not available.
2. Studies in animals.
3. Health conditions that may inﬂuence dietary intake (i.e., gestational diabetes,
celiac disease, malnutrition, etc.).
4. Studies done in virtual populations.
5. Studies without a random sample.
CHF¼ congestive heart failure.
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appropriate randomization procedure (A), inappropriate randomi-
zation (B), or unclear (C). Allocation of concealment was rated as:
concealed appropriately (A), not concealed (B), or unclear (C).Table 2
Details of included studies.
Ref Country N Sex ratio (F:M) Mean age (y) ±
[24] Italy 13 2:11 59± 14
[25] Germany 15 1:14 61± 6
[26] Italy 23 3:20 59± 9
[27] United Kingdom & Poland 35 10:25 63± 12
[28] United Kingdom 70 15:55 57± 2
[29] Germany 15 Unclear 59± 4
[30] Ukraine 98 Unclear Unclear
[31] Germany 123 21:102 55± 3
[32] Iran 64 10:54 63± 8
[10] United Kingdom 32 Unclear 75± 4
[33] Canada 41 Unclear 65± 8
F¼ Female; M¼Male; N¼ number of patients in each treatment arm; NYHA¼New Yor
Table 3
Results of studies analyzing the effectiveness of single micronutrient on heart failure pa
Ref Y Intervention Dose N
EF ET FC
[24] 2014 Amino Acid
L-Leucine
L-Lysine
L-Isoleucine
L-Valine
L-Threonine
L-Cystine
L-Hystidine
L-Phenylalanine
L-Methionine
L-Tyrosine
L-Triptophan
4 g
1250 mg
650 mg
625 mg
625 mg
350 mg
150 mg
150 mg
100 mg
50 mg
30 mg
20 mg
13 Y Y Y
[25] 2003 D-Ribose 5 g 15 Y Y No
[26] 2006 Coenzyme Q10 100 mg 23 Y No Y
[27] 2008 Iron 200 mg 35 Y Y No
[28] 2000 Vitamin C 2 g twice daily 70 No No No
[29] 1998 Vitamin C 25 mg/min IA 15 No No No
[30] 2013 Magnesium 1000 mg 3 times/d 98 No No No
[31] 2006 Vitamin D 50 g Vitamin D3 123 No No No
EF¼ ejection fraction; ET¼ exercise tolerance; FC¼ functional capacity; LVSF¼ left ve
proBNP¼N-terminal pro b-type natriuretic peptide; PTH¼ parathyroid hormone; QOL¼Blindingwas rated as: double-blind (A), single blind (B), no blinding
(C), or unclear (D). Sample size calculation was assessed as:
appropriate calculation procedure (A), inappropriate calculation
(B), or unclear (C). The drop-out rate (loss to follow-up) was
assessed as: 5.0% (A), 5.1e10.0% (B), 10.1e15.0% (C), > 15.0% (D), or
unclear (E) [23].
3. Results
The 11 included studies were classiﬁed into trials that included
only a single micronutrient and those that included multiple
micronutrients, as shown in Table 2.
3.1. Primary and secondary outcomes
Tables 3 and 4 summarize results from all 11 studies. Only
eight trials had clearly deﬁned primary and secondary outcomes
of interest [10,24e27,31e33]. In the remaining three trials, the
reported outcome measures were mostly reduction of inﬂamma-
tory milieu, improvement in ﬂow-dependent dilation, and
normalization of endothelial dysfunction and carbohydrate
metabolism [28e30].SD Duration of symptoms Intervention Follow-up (mo)
HF for 6 mo
in NYHA class II
or III, with an
ejection fraction 45%
Single micronutrient 3
Unclear Single micronutrient 6
Unclear Single micronutrient Unclear
Unclear Single micronutrient 16
Unclear Single micronutrient Unclear
Unclear Single micronutrient 1
Unclear Single micronutrient Unclear
Unclear Single micronutrient 15
Unclear Multiple micronutrients 3
Unclear multiple micronutrients 25
Unclear Multiple micronutrients Unclear
k Heart Association; SD¼ standard deviation.
tients.
Primary & secondary outcomes
LVSF QOL Others
No No Peak VO2, VO2 at anaerobic threshold improved signiﬁcantly,
reduction of NT-proBNP levels
No Y Enhances diastolic function
No No Improves endothelial function, LV contractility
No Y Improved exercise capacity & symptoms
No No Reduces oxidative stress, increases ﬂow-mediated dilation
No No Improves endothelial function
No No Normalizes endothelial dysfunction & carbohydrate metabolism
Y No Anti-inﬂammatory agent, suppress serum PTH
ntricular systolic function; N¼ number of patients in each treatment arm; NT-
quality of life; Y ¼ yes.
Table 4
Results of studies analyzing effectiveness of multiple micronutrients on heart failure patients.
Ref Y Intervention/dose N Primary & secondary outcomes
EF ET FC LVSF QOL Others
[32] 2015 Selenium 200 mg & Coenzyme Q 30 mg 64 Y No No Y No Improvement of NYHA classes
[10] 2005 Calcium 250 mg Magnesium 150 mg
Zinc 15 mg
Copper 1.2 mg
Selenium 50 mg
Vitamin A 800 mg
Thiamine 200 mg
Riboﬂavin 2 mg
Vitamin B6 200 mg
Folate 5 mg
Vitamin B12 200 mg
Vitamin C 500 mg
Vitamin E 400 mg
Vitamin D 10 mg
Co-enzyme Q10 150 mg
32 Y No No Y Y
[33] 2002 MyoVite per 250 mL contains:
Energy 200 kcal
Protein 15 g
Carbohydrates 17.7 g
Fat 7.8 g
Carnitine 3.0 g
Coenzyme Q10 150 mg
Taurine 3.0 g
Creatine 2.25 g
Sodium 108 mg
Potassium 750 mg; Chloride 203 mg
Calcium 315 mg
Phosphorus 183 mg
Magnesium 20 mg
Iron 1.0 mg
Zinc 15 mg
Copper 1.5 mg
Manganese 3.0 mg
Fluoride 1.0 mg
Molybdenum 50 mg
Selenium 50 mg
Chromium 33 mg
Iodine 100 mg
Retinol ester 688 mg
Cholecalciferol 5 mg
a-Tocopherol acetate 538 mg
Thiamin 25 mg
Riboﬂavin 3.0 mg
Niacin 20 mg
Pantothenate 4.0 mg
Pyridoxine 6.0 mg
Folate 600 mg
Cyanocobalamin 3.0 mg
Biotin 100 mg
Ascorbate 250 mg
41 Y No No No No Reduction in left ventricular
end-diastolic volume in patients
EF¼ ejection fraction; ET¼ exercise tolerance; FC¼ functional capacity; LVSF¼ left ventricular systolic function; N¼ number of patients in each treatment arm; NYHA¼New
York Heart Association; QOL¼ quality of life; Y ¼ yes.
Table 5
Methodological quality of studies included in the review.
Ref Y Randomization Allocation
concealment
Sample size
calculation
Blinding Lost to
follow-up
[24] 2014 C C C D E
[25] 2003 A C C A E
[26] 2006 A C C D A
C. Valiyakizha Kkeveetil et al. / Tzu Chi Medical Journal 28 (2016) 143e150 1473.2. Methodological quality of trials
Table 5 summarizes the quality of the 11 studies. There was a
70% loss to follow up in one study [33] and 25% loss to follow up in
another [31]. It was unclear how randomization was carried out in
four of the trials [24,28e30]. There were no data available on how
allocation concealment was done in any of the studies and it was
unclear how blinding was done in six trials [24,26e30].[27] 2008 A C C D C
[28] 2000 C C C D E
[29] 1998 C C C D E
[30] 2013 C C C D E
[31] 2006 A C C A D
[32] 2015 A C A A A
[10] 2005 A C C A E
[33] 2002 A C C A D
A¼XX; B¼XX; C¼XX; D¼XX; E¼XX.3.3. Heterogeneity of trials
All 11 trials were heterogenous in that they had various inclu-
sion and exclusion criteria and different treatment protocols, which
are shown in Tables 2 and 3. The investigated micronutrients were
amino acids by Lombardi et al [24], coenzyme Q10 (CoQ10) by
C. Valiyakizha Kkeveetil et al. / Tzu Chi Medical Journal 28 (2016) 143e150148Belardinelli et al [26], ribose by Omran et al [25], iron by Okonko
et al [27], magnesium orotate by Krapivko and Omelchenko [30],
selenium by Garakyaraghi et al [32], vitamin C by Ellis et al [28], and
vitamin D by Schleithoff et al [31]. In the remaining three trials,
various combinations of micronutrients were investigated
[10,32,33].3.4. Micronutrients versus no micronutrients
All 11 trials compared the use of micronutrients versus no
micronutrients in HF patients. The most commonly used outcome
measure was the ejection fraction (EF), which was used in four
trials of single micronutrients and three trials of multiple micro-
nutrients. Hence, the mean EF was used as a single parameter to
assess the effectiveness of micronutrients in HF patients. The mean
EF increased 2% from baseline after iron supplementation, 6% after
using CoQ10, 1% after amino acid use, and 1% after D-ribose use.
This is depicted in Fig. 3.Fig. 3. Mean decrease in ejection fraction (EF) in four trials
Fig. 4. Mean decrease in ejection fraction (EF) inIn trials using multiple micronutrients, the trial by Jeejeebhoy
et al [33], documented a 0.9% increase in mean EF from baseline
after treatment compared with a 3.7% increase in the trial by
Garakyaraghi et al [32], and a 5.3% increase in the trial of Witte et al
[10]. This is illustrated in Fig. 4.4. Discussion
The data obtained from this review show that many micro-
nutrients including amino acids have a signiﬁcant role in improving
the disease outcome in HF patients. It is evident that different
micronutrients display various mechanisms to arrive at this
outcome. In HF patients, there is a reduced availability of amino
acids leading to abnormalities in cardiac and skeletal muscle
metabolism and eventually to a reduction in functional capacity
and quality of life [24]. In cardiac metabolism, amino acids play a
dual role. They act both as “building blocks” of proteins and are
intermediary metabolites in energy substrate metabolism. Taurineusing a single micronutrient. CoQ10¼ coenzyme Q10.
three trials using multiple micronutrients.
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and can be synthesized from methionine or cysteine, and, as such,
is not an essential amino acid. It is an antioxidant and is an
important endogenous regulator of intracellular calcium homeo-
stasis [13]. CoQ10, or ubiquinone, is an important component as a
redox carrier in the mammalian respiratory transport [34] in
mitochondria and serves as a carrier for electrons ﬂowing through
complexes I, II, and III. CoQ10 essentially helps in ATP formation in
tissues, including the heart, skeletal muscle, brain, kidney, and liver
[13]. As the myocardium of patients with HF demonstrates oxida-
tive stress, CoQ10 prevents lipid peroxidation and thus prevents
myocardial destruction. Therefore, it acts as an antioxidant scav-
enger. In HF patients, the concentration of CoQ10 decreases in
myocardial cells and the extent of myocardial CoQ10 deﬁciency
correlates with the clinical severity of HF [35]. Vitamin D is a
prosteroid hormone [36], which plays an important role in the
homeostasis of calcium, which in turn is a key player in cardiac
contractility [13]. Witte et al [6] found deterioration of myocardial
contraction when patients were given a diet low in vitamin D.
Furthermore, after vitamin D supplementation, it was found that
the myocardium returned to normal function.
A naturally-occurring pentose sugar, ribose, was shown exper-
imentally to enhance the recovery of depressed myocardial ATP
levels and improve myocardial diastolic compliance following
ischemia. In cardiac metabolism, D-ribose aids by entering the
pentose phosphate pathway to form ribose-5-phosphate and by-
passes the rate-limiting enzymes of glucose-6 phosphate dehy-
drogenase and 6-phosphogluconate dehydrogenase. A reduced
level of myocardial ATP leads to diastolic dysfunction [25].
A deﬁciency of magnesium, which is known to cause signiﬁcant
life-threatening ventricular arrhythmias and sudden death, can be
treated with magnesium supplements. In addition, magnesium
deﬁciency may cause myocardial ﬁbrosis and platelet aggregation,
thus explaining its overall adverse effect on cardiovascular mor-
tality. Aldosterone, a harmful neurohormone (activated in HF), also
increases urinary excretion of magnesium causing low serum
magnesium. Thus, low serum magnesium may also be a marker of
disease progression in HF [37].
There is documented evidence that deﬁciencies of CoQ10, B
vitamins, and L-carnitine lead to a failing heart. Deﬁciency in
potassium leads to arrhythmia in HF patients. Zinc is an antiox-
idant found to be deﬁcient in HF, but there is no clear evidence of
its association with progression of HF. Deﬁciency of selenium also
leads to endothelial dysfunction and cardiomyopathy [13]. There
is evidence that vitamin C inhibits endothelial cell apoptosis in
CHF patients [38]. Hence, as in our study, almost all micro-
nutrients play a major role in improving the health outcomes in
HF patients.
A clinical trial using micronutrient therapy for HF patients is
ongoing with the trial registration number NCT01005303. The
study is ongoing so it was not included in this review.
5. Conclusion
Disturbances in minerals and micronutrients are an integral
feature of HF and likely contribute to the progressive nature of this
disease. These disturbances relate to reduced sunlight exposure
and dietary calcium intake along with intake of loop diuretics and
angiotensin converting enzyme inhibitors, which are standard in
the care of HF patients today. Based on the set of studies included
here, micronutrients appear to have a positive impact on the dis-
ease outcomes of HF patients. Based on the data presented here, we
strongly feel that patients with HF need daily nutrient supple-
mentation in addition to their habitual diet and regular pharma-
cological and nonpharmacological treatment.References
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